Celltrion’s Herzuma was the first biosimilar of Roche’s Herceptin, a blockbuster HER2-targeted therapy, to launch in Europe. A few months later, three additional trastuzumab biosimilars launched in Europe: Merck & Co.’s Ontruzant Amgen’s Kanjinti, and Pfizer’s Trazimera. This series tracks uptake of these biosimilars and medical oncologists’ awareness of these agents in order to gauge their impact on the commercially lucrative breast cancer and gastroesophageal cancer therapy markets. The series investigates perceptions of trastuzumab biosimilars, drivers of and barriers to their use, and future use expectations. Promotional efforts, prescriber and nonprescriber profiles, and benchmarking of these agents’ launch success versus that of other launched biosimilars are explored to better understand the dynamics of the German biosimilars market.

QUESTIONS ANSWERED

  • Are German medical oncologists aware of Herzuma, Ontruzant, Kanjinti, and Trazimera?
  • What are the drivers of prescribing of Herzuma, Ontruzant, Kanjinti, and Trazimera?
  • What is the current level of Herzuma, Ontruzant, Kanjinti, and Trazimera use, and how is it changing over time?
  • Are German physicians prescribing Herzuma, Ontruzant, Kanjinti, or Trazimera in combination with Perjeta?
  • Have physicians experienced pressure to prescribe Herzuma, Ontruzant, Kanjinti, and Trazimera?
  • What promotional messages are sales representatives using for Herzuma, Ontruzant, Kanjinti, Trazimera, and Herceptin?

PRODUCT DESCRIPTION

Emerging Biosimilars (Germany) is a three-wave series based on primary research data collected at 1 month, 6 months, and 12 months postcommercial launch with German physicians. The research captures physicians’ awareness, perceptions, and use of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

RELEASE DATE

Wave 1: September 2018.

Wave 2: February 2019.

Wave 3: July 2019.

GEOGRAPHY

Germany.

PRIMARY RESEARCH

A survey of 60 medical oncologists.

Key metrics included

  • Unaided and aided awareness of Herzuma, Ontruzant, Kanjinti, and Trazimera.
  • Familiarity with and impressions of Herzuma, Ontruzant, Kanjinti, and Trazimera.
  • Prescriber and nonprescriber profiles.
  • Willingness to prescribe Herzuma, Ontruzant, Kanjinti, and Trazimera.
  • Performance of Herzuma, Ontruzant, Kanjinti, and Trazimera on key attributes.
  • Sales representative frequency, reach, and satisfaction.
  • Benchmarking against previously launched biosimilars.

Table of contents

  • Biosimilars - Emerging Biosimilars - Oncology: Trastuzumab Biosimilars Launch Tracking (Germany) Wave 3

Author(s): Jimmy Jacob

Jimmy Jacob, Ph.D. is a Business Insights Analyst in the Biosimilars team. Prior to joining DRG, Jimmy worked as a Scientist in Medimmune and Horizon Discovery mostly involving CRIPSR/Cas9 therapeutics. He received his master’s degree in Biotechnology from University of Dundee and his Ph.D. from Imperial College London. His Ph.D. work involved identifying novel molecules that regulated oestrogen receptor-alpha in breast cancer.


Related Reports

Biosimilars - Emerging Biosimilars - Special Topics: Oncology Biosimilars In The United States - Wave 1

Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the seco...

View Details

Oncology Clinical Trial Monitor - Clinical Trials - Oncology Clinical Trial Monitor

Oncology Clinical Trial Monitor is a continuously updated dashboard, highlighting the global immuno-oncology clinical development landscape and clinical outcomes for key standards of care. This dyn...

View Details

Biosimilars - Market Events And Forecast - Oncology

In 2018, sales of branded monoclonal antibody biologics in oncology exceeded $20 billion across the major markets (United States, EU5, and Jap...

View Details

Biomarkers In Oncology - Access & Reimbursement - Detailed, Expanded Analysis: Multi-indication (US)

Biomarker-driven prescribing is paramount in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small-cell lung cancer and malignant mela...

View Details